🔗 Share this article

Given that the US continues making sweeping changes to its immunization guidelines, a particular individual appears unexpectedly: Høeg, a US-based physician and epidemiologist who initially gained attention by questioning Covid vaccines in the pandemic and has focused upon possible fatalities after COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Proposed Shifts to Pediatric Vaccine Program

Public health authorities planned to announce radical revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with Denmark’s national calendar, it is understood – a substantial departure that would put the US at odds with much of the world with insufficient data for benefit. The planned update has been postponed until the new year.

Instead of Vinay Prasad, Dr. Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s CDER, the fifth appointee to run the office this year.

A Shift at the Regulatory Body

This interim role may indicate a closer partnership between the drug and vaccine branches as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a renewed priority upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more like Denmark, a country with nationalized medicine and a citizenry approximately the population of the state of Wisconsin.

In her initial public appearances, she has continued to focus on immunizations – usually the purview of Prasad, director of the FDA’s CBER – rather than drug regulation.

Questions Over Background

The appointee has no apparent experience in drug development, approval processes or management, which has been standard for former directors of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and CBER since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, stated Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Former directors of the center would “be deeply familiar with legal statutes and the science of pharmaceutical innovation”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who led CBER have had.”

CDER has an enormous workload at the FDA, she emphasized.

“Everybody just pays attention on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars program, non-prescription drug unit and more, and each of these must be supervised,” she said. “The thing you neglect, that is the part that I always told people is going to bite you.”

Additionally, a substantial management component to the role, which oversees more than 5,000 employees. “It is a massive administrative position, if you do it right,” the former official said.

Agency Reaction and Contentious Initiatives

When asked about questions about Dr. Høeg's credentials and whether this selection represents more teamwork among agency officials on immunizations, a representative responded that the “questions are based on inaccurate premises”.

“Her experience matches the responsibilities of her role,” the spokesperson said, pointing to the months Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the agency head's new priority voucher program, a contentious one-day therapy clearance system that allegedly troubled her preceding directors. “By what process are these drugs being picked for this fast-track system? Who makes the calls?” Howard asked. “There is a lot of secrecy happening at the agency right now.”

In general, he remarked, “the FDA appears to be shifting towards laxer regulations of all drugs, except for shots.”

Public Past Work on Vaccines

Concerning vaccines, Høeg has a clearer, if concerning, past, Howard have noted. She authored a research paper using unconfirmed volunteer-provided data to determine the rate of heart inflammation after COVID-19 vaccination. She consulted for the Florida top health official Dr. Joseph Ladapo, who allegedly have changed statistics to imply Covid vaccines are riskier than they are.

Among her “wish list” for the new federal leadership featured revising rules for novel immunizations and discontinuing “optional” vaccines, she stated after the election on a audio program. At the agency, Dr. Høeg has according to sources suggested barring young men from getting Covid vaccinations.

“She’s an complete true believer who commences with her preconceived notions and reverse-engineers to fit the evidence in a extremely misleading, fraudulent fashion,” Dr. Howard said.

Consolidating Power and a “Push for Payback”

Høeg aligned with fellow dissenters, {like|